AbbVie has partnered with psychedelic biotechnology company Gilgamesh Pharmaceutical to develop advanced treatment methods for psychiatric disorders.
The partnership will leverage AbbVie's psychiatric expertise and Gilgamesh's research platform to create novel "neuroplastogens." These next-gen compounds are expected to provide significant clinical benefits while reducing psychoactive side effects. Under the terms of the agreement, AbbVie will have the option to lead development and commercialization activities.
Further, AbbVie will pay Gilgamesh USD 65 million upfront, with potential future payments reaching up to USD 1.95 billion based on certain milestones and sales-related royalties.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.